Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4393687 | 0.85 | CYP3A4 (0.35) | CYP3A4TSHRPIK3CAALDH1A1 | |
| SCHEMBL5460684 | 0.84 | CD44 (0.39) | CD44CYP3A4TSHRPIK3CA | |
| SCHEMBL5465268 | 0.83 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL5462581 | 0.83 | IDO1 (0.32) | ALDH1A1 | |
| SCHEMBL5465608 | 0.72 | NOS3 (0.40) | — | |
| SCHEMBL1431415 | 0.72 | CYP3A4 (0.33) | CYP3A4TSHRPIK3CA | |
| SCHEMBL8512559 | 0.72 | CD44 (0.48) | CD44CYP3A4TSHRPIK3CAALDH1A1 | |
| SCHEMBL6028201 | 0.72 | CD44 (0.48) | CD44CYP3A4TSHRPIK3CAALDH1A1 | |
| SCHEMBL106624 | 0.70 | LPL (0.31) | — | |
| SCHEMBL1922650 | 0.69 | KDM4E (0.33) | CYP3A4TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541367-B2 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-02 | — | — | US | disclosed |
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-02-19 | — | — | US | disclosed |
| WO-2006130673-A1 | 3-BENZOIMIDAZOLYL-PYRAZOLOPYRIDINES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048249-A1 | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders | PRKDC, PRKACA, ABL1 | CD44 4815/4885CYP3A4 3719/4885TSHR 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.